摘要
目的：对低分子肝素治疗肺心病并呼吸衰竭的临床效果进行研究。方法选取2013年7月～2015年7月我院接受治疗的肺心病并呼吸衰竭患者97例，将患者随机分为对照组（46例）和治疗组（51例）进行对照组研究，观察常规治疗和低分子肝素治疗的效果并进行比较。结果治疗组患者的显效率、好转率以及治疗总有效率分别为60.8%、31.4%和92.2%，均高于对照组患者的47.8%、23.9%和28.3%，差异具有统计学意义（P ＜0.05）。结论对肺心病并呼吸衰竭采用低分子肝素治疗具有疗效，能使治疗效果得到显著提高，使患者的缺氧情况、肺循环以及呼吸功能得到改善。
Objective To LMWH pulmonary heart disease and respiratory failure were studied clinical results. Methods In July 2013 to July 2015 in our hospital for treatment of respiratory failure in patients with pulmonary heart disease and 97 cases, the patients were randomly divided into control group （46 cases） and treatment group （51 patients） in the control group study, the observed effect of conventional treatment and low molecular weight heparin and compared. Results The treatment group were significantly efficiency improvement rate and the total effective rate was respectively 60.8%, 31.4% and 92.2%, significantly higher than 47.8% of patients, 23.9% and 28.3%, significantly different statistically significance （P〈0.05）. Conclusion Pulmonary Heart Disease and Respiratory Failure using low molecular weight heparin having a significant effect, the therapeutic effect can be significantly improved and the hypoxia, pulmonary circulation and respiratory function of patients improved.
出处
《中国继续医学教育》
2015年第25期146-147,共2页
China Continuing Medical Education
关键词
低分子肝素
肺心病
呼吸衰竭
Low molecular weight heparin
Pulmonary heart disease
Respiratory failure
